Officials at the Massachusetts Institute of Technology are suing ImClone, the makers of a promising new cancer drug called Erbitux. The university says the drug is manufactured using technology patented by the school 20 years ago. Fights between universities and companies that use their research are becoming much more common. NPR's Snigdha Prakash reports.
NPR transcripts are created on a rush deadline by a contractor for NPR, and accuracy and availability may vary. This text may not be in its final form and may be updated or revised in the future. Please be aware that the authoritative record of NPR's programming is the audio.